GeneTx, Ultragenyx (RARE) Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome
Go back to GeneTx, Ultragenyx (RARE) Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 29.03 +1.59 (5.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.44 | 52 Week High | $117.12 | |||
| Open | $27.56 | 52 Week Low | $46.52 | |||
| Day High | $29.35 | P/E | N/A | |||
| Day Low | $27.49 | EPS | $-1.97 | |||
| Volume | 2,067,508 | |||||
